Results 31 to 40 of about 616,145 (212)

Perioperative detection of circulating tumour cells in patients with lung cancer [PDF]

open access: yes, 2017
© 2017 Chudasama et al. Lung cancer is a leading cause of mortality and despite surgical resection a proportion of patients may develop metastatic spread.
Alexandra Rice   +24 more
core   +1 more source

"Person in the barrel" syndrome: Unusual heralding presentation of squamous cell carcinoma of the lung

open access: yesAnnals of Indian Academy of Neurology, 2016
Paraneoplastic neurological syndromes (PNS) are rare and relatively unusual in day to day clinical practice. Occasionally, PNS may be the heralding manifestation of the malignancy.
Rajesh Verma   +3 more
doaj   +1 more source

Changing trends in incidence of lung cancer by histological type in Montenegro [PDF]

open access: yesSrpski Arhiv za Celokupno Lekarstvo, 2014
Introduction. Lung cancer is one of the most common malignant neoplasms, as well as the most common cause of death cancer. Most lung cancers are squamous cell carcinomas, small cell carcinomas or adenocarcinomas. Objective.
Medenica Milić   +4 more
doaj   +1 more source

Lung cancer: risk factors, management, and prognosis [PDF]

open access: yes, 2016
Lung cancer or lung tumor the most common cause of cancer death in men and second most common in women after breast cancer. Highest rates in North America, Europe, and East Asia, with one third of new cases in China, lower rates in Africa and South Asia.
A. Nazirah   +5 more
core   +1 more source

A Case Report of Small Cell Lung Carcinoma in a Patient with Progressive Diffuse Sclerosis

open access: yesJournal of Mazandaran University of Medical Sciences, 2022
Connective tissue diseases, including scleroderma, may be associated with an increased risk of lung cancer. The most common type of lung cancer associated with systemic sclerosis is adenocarcinoma or bronchoalveolar carcinoma, and small cell carcinoma is
Hojatolah Ghorbani   +4 more
doaj  

Genetic variant of miR-4293 rs12220909 is associated with susceptibility to non-small cell lung cancer in a Chinese Han population. [PDF]

open access: yesPLoS ONE, 2017
Non-small cell lung cancer is one of the most common cancers and the leading cause of cancer death worldwide. Genetic variants in regulatory regions of some miRNAs might be involved in non-small cell lung cancer susceptibility and survival. rs12220909 (G/
Lixia Fan   +19 more
doaj   +1 more source

Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma [PDF]

open access: yes, 2014
Lineage transition in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) of non-small cell lung cancer, as implicated by clinical observation of mixed ADC and SCC pathologies in adenosquamous cell carcinoma, remains a fundamental yet unsolved ...
Chen, Haiquan   +19 more
core   +1 more source

RET in non-small cell lung carcinoma

open access: yesCancer Research, Statistics, and Treatment, 2021
The advent of stratified medicine and tailored therapies has caused non-small cell lung cancer (NSCLC) to become a subject of keen interest, with an emphasis on comprehensive genomic testing for driver mutations and biomarkers. The rearranged during transfection (RET) gene rearrangement has been observed in 1%–2% of all NSCLCs.
Shrinidhi Nathany   +2 more
openaire   +1 more source

Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with review of literature

open access: yesLung India, 2018
A subset of non-small cell lung carcinoma (NSCC) harbor active mutations of epidermal growth factor receptor (EGFR). In these, EGFR tyrosine kinase inhibitors (EGFR-TKIs) are recommended as the first-line treatment.
Monalisa Hui   +3 more
doaj   +1 more source

Study of PD-L1 Expression in Tumours Based on Site and Histology of Tumour – The Experience of a Tertiary Referral Laboratory

open access: yesAsian Pacific Journal of Cancer Biology, 2023
Background: PD-L1 IHC test is used as a predictive biomarker using FDA-approved assays to select patients likely to benefit from immunotherapy in several advanced-stage tumors. We aim to present our data regarding the prevalence and expression pattern of
Vinita Pant, Munmun Harlalka
doaj   +1 more source

Home - About - Disclaimer - Privacy